Fluoxetine

Generic Name: Fluoxetine

Brand Names: Prozac, Sarafem, Symbyax

Drug Type: Small Molecule

Chemical Formula: C_₁₇H_₁₈F_₃NO

CAS Number: 54910-89-3

Unique Ingredient Identifier: 01K63SUP8D

Background: Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.

Indication: Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar ...

Associated Conditions: Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)

Associated Therapies: Maintenance therapy

Clinical Trials

FDA sidesteps MDMA controversy at PTSD meeting, but public pushes back

FDA meeting on PTSD treatments reignited debate over delayed approval of Lykos Therapeutics' MDMA-assisted therapy. Critics, including Dr. Robert M. Grant, argue FDA's review failed, citing inconsistent guidance and unmet needs for better PTSD treatments. Despite FDA's cautious approach, veterans and researchers advocate for urgent action, highlighting the growing disconnect between FDA's stance and the insistent needs of potential beneficiaries. MAPS plans to continue Phase 3 trials and educate healthcare providers and policymakers, aiming to provide access to treatments regardless of FDA requirements.

bostonglobe.com

4 months ago

Moderna, Takeda, and other Boston biotechs display work by disadvantaged artists

ArtLifting, founded by Liz and Spencer Powers, brokers art by disadvantaged artists, earning them $6.5 million. Their works, including by Allen Chamberland and Lisa Murphy, are displayed in corporate offices, including Moderna and Foundation Medicine, aiming to break stigmas and provide income.

Fluoxetine

FDA sidesteps MDMA controversy at PTSD meeting, but public pushes back

Moderna, Takeda, and other Boston biotechs display work by disadvantaged artists

Drug Development Updates